

1 **Optimal Delivery Management for the Prevention of Early Neonatal SARS-CoV-2**  
2 **Infection: Systematic review and Meta-analysis**

3  
4 Christina S Chan [1] [†], Juin Yee Kong [2] [†], Rehena Sultana [3], Vatsala Mundra [4],  
5 Kikelomo L Babata [1], Kelly Mazzarella [1], Emily H Adhikari [5], Kee Thai Yeo [2], Jean-  
6 Michel Hascoët [6], Luc P Brion [1]

7  
8 Contact Person: Christina S Chan ([christina.chan@utsw.edu](mailto:christina.chan@utsw.edu))

9 Pediatrics / Div. Neonatal-Perinatal Medicine

10 University of Texas, Southwestern Medical Center

11 5323 Harry Hines Boulevard

12 Dallas, Texas 75390 USA

13  
14 [1] Pediatrics / Div. Neonatal-Perinatal Medicine, University of Texas, Southwestern Medical  
15 Center, Dallas, Texas, USA

16 [2] Department of Neonatology, KK Women's and Children's Hospital, Singapore, Singapore

17 [3] Centre for Quantitative Medicine, Duke – NUS Medical School, Singapore

18 [4] School of Medicine, University of Texas, Southwestern Medical Center, Dallas, Texas, USA

19 [5] Department of Obstetrics and Gynecology, University of Texas, Southwestern Medical  
20 Center, Dallas, Texas, USA

21 [6] Lorraine University, DevAH, CHRU Nancy, France

22

23 **CITATION:**

- 1 Chan CS, Kong JY, Sultana R, Mundra V, Babata KL, Mazzearella K, Adhikari EH, Yeo KT,
- 2 Hascoët JM, Brion LP. Optimal delivery management for the prevention of early neonatal
- 3 SARS-CoV-2 infection: Systematic review and meta-analysis
- 4
- 5 **Word count:** 2494

1 **ABSTRACT:**

2

3 **Objective:** Review how specific delivery management interventions (DMI) are associated with  
4 early neonatal SARS-CoV-2 infection (ENI) and neonatal death <28 days of life (ND).

5

6 **Design:** Systematic review and meta-analysis of individual patient-specific data from articles  
7 published 1 January 2020 - 31 December 2021 from Cochrane review databases, Medline and  
8 Google Scholar.

9

10 **Setting:** International publications specifying DMI, ENI, and ND.

11

12 **Patients:** Pregnant women infected with SARS-CoV-2 and their infants

13

14 **Main outcome measures:** Article inclusion criteria: 1) mothers with SARS-CoV-2 PCR positive  
15 status within 10 days before delivery or symptomatic at delivery with a positive test within 48  
16 hours after delivery, 2) delivery method described, 3) infant SARS-CoV-2 PCR result reported.  
17 Primary outcomes were 1) ENI confirmed by positive neonatal PCR and 2) ND.

18

19 **Results:** Among 11,075 screened publications, 117 publications containing data for 244 infants  
20 and 230 mothers were included. Maternal and infant characteristics were pooled using  
21 DerSimonian-Laird inverse variance method. Primary outcome analyses were completed using  
22 logit transformation and random effect. Heterogeneity of included studies was evaluated with  $I^2$   
23 statistics.

1

2 No routine care was described so comparison of DMI combinations to routine care was not  
3 possible. Sample size for each combination was too small to conduct any valid comparison of  
4 different DMI combinations.

5

6 **Conclusion:** Support for specific DMI in SARS-CoV-2 infected mothers is lacking. This review  
7 highlights the need for rigorous and multinational studies on the guidelines best suited to prevent  
8 transmission from mother to neonate.

9

10 **Keywords:** COVID-19; SARS-CoV-2; neonates; coronavirus; delivery

11

12 **Abbreviations:**

13 DMI: delivery management interventions

14 ENI: early neonatal SARS-CoV-2 infection

15 ND: neonatal death (<28 days of life)

16 SARS-CoV-2: severe acute respiratory syndrome coronavirus 2

17 COVID-19: coronavirus disease of 2019, the disease caused by SARS-CoV-2 virus

18

19 Word count: 2494

1 **KEY MESSAGES:**

2

3 **What is already known on this topic**

4 Several specific delivery management interventions (DMI) have been recommended for women  
5 with active SARS-CoV-2 to prevent early neonatal SARS-CoV-2 infection.

6 **What this study adds**

7 This systematic review shows that support for specific DMI in SARS-CoV-2 infected mothers is  
8 lacking.

9 **How this study might affect research, practice or policy**

10 This review highlights the need for rigorous and multinational studies on the guidelines best  
11 suited to prevent transmission from mother to neonate.

12

1 **SETTING:**

2 The first case of coronavirus disease of 2019 (COVID-19) was reported from China in  
3 November 2019. It was later found to be caused by a novel virus named severe acute respiratory  
4 syndrome coronavirus 2 (SARS-CoV-2)<sup>1,2</sup>. On 30 January 2020, the World Health Organization  
5 <sup>2</sup> declared the outbreak a Public Health Emergency of International Concern<sup>3</sup>. By 11 March  
6 2020, COVID-19 was characterized as a global pandemic<sup>2</sup>. The rapid progression of COVID-  
7 19/SARS-CoV-2 dramatically impacted healthcare, especially for pregnant women and infants at  
8 increased risk for maternal death, severe maternal morbidities, and neonatal morbidities<sup>4</sup>. With  
9 significant numbers of pregnant women infected with SARS-CoV-2, lack of consistent vaccine  
10 availability in many countries, and vaccine hesitancy especially for pregnant women, evidence  
11 for practice recommendations designed to reduce transmission to infants remains a pressing  
12 concern.

13  
14 The mode and significance of SARS-CoV-2 transmission from mother to fetus or infant remains  
15 unclear. Confirmation of diagnosis and source of transmission is challenging, given the subtle  
16 presentation of symptoms and clinical course in newborn infants and the possible close contact  
17 of multiple caregivers who may be infectious<sup>5</sup>. With available case reports, it has been  
18 challenging to accurately determine exact timing or route of transmission as this would require  
19 extensive testing including immunocytochemistry, in situ hybridization and/or RT-PCR in all  
20 possible pregnancy and delivery material (placenta, amniotic fluid, vaginal secretions, colostrum,  
21 blood, stools, urine, nasopharyngeal secretions in the mother), and serially timed PCR sampling  
22 of the infant and sampling among all caregivers.

23

1 **PATIENTS:**

2  
3 To date, there has been no systematic review or study comparing combinations of delivery  
4 management interventions (DMI) with routine care and the risk of early neonatal infection (ENI)  
5 or neonatal death before 28 days of life (ND). Differing opinions from various expert consensus  
6 guidelines make the best choices for DMI challenging. Many suggest shared decision-making  
7 between healthcare providers and patients for management during the perinatal period <sup>6</sup>. With the  
8 ubiquitous burden of this disease, it remains important to assess DMI that could minimize ENI  
9 and ND while ensuring safety and optimal care to both mother and infant.

10

11 **IN UTERO INFECTION:**

12 In utero infections have now been documented. Between 1% and 15% of adults with COVID-19  
13 have RNAemia and pregnant women are more susceptible to COVID-19 than the general  
14 population<sup>1, 7</sup>. Physiologic mechanisms for in utero infections include angiotensin-converting  
15 enzyme 2 (ACE2), the receptor of SARS-CoV-2 as an integral component of human to human  
16 transmission that is <sup>8</sup> expressed in maternal-fetal interface cells <sup>9</sup>, placenta <sup>10, 11</sup> as well as several  
17 fetal organ cells <sup>9, 12</sup>. Detection of SARS-CoV-2 RNA in pharyngeal or stool specimens of  
18 infants born to mothers with a remote history of SARS-CoV-2 infection during pregnancy,  
19 suggests possible congenital infection as persistence of the virus is expected for up to five weeks  
20 after onset of symptoms <sup>13</sup>. In-utero infection with SARS-CoV-2 has been suggested via the  
21 amniotic fluid <sup>14</sup> as well as placenta <sup>15</sup>. The detection of IgM in infants shortly after birth despite  
22 failure to isolate viral RNA also suggests the transmission of infection prior to delivery <sup>16-19</sup>.

23

1 PERINATAL INFECTION:

2 In addition, perinatal transmission of SARS-CoV-2 may also be possible during labor and  
3 delivery. In the immediate postnatal period, direct exposure of infants to infected maternal stool,  
4 blood or amniotic fluid can increase transmission risk to the infant <sup>20</sup>. There is also theoretical  
5 risk of airborne transmission from mothers who have experienced a recent aerosol-generating  
6 procedure such as intubation or electrocautery of surgical wound <sup>21</sup>. There has also been a  
7 suggestion that the second stage of labor, while not typically described as an aerosol-generating  
8 event, is a period when mothers may be breathing heavily, shouting, coughing, or vomiting - all  
9 activities that increase risk of aerosol exposure <sup>20</sup>.

10

11 EARLY NEONATAL INFECTION:

12 ENI may be evident between 12 hours of life and 15 days of life with the average incubation  
13 period of five days <sup>22</sup>. For this review's purposes, we define ENI as neonatal SARS-CoV-2 PCR-  
14 positive between 12 hours and 10 days of life. This may include in utero and perinatal infection.  
15 Beyond this period, delivery management is less likely to affect whether an infant is SARS-CoV-  
16 2-positive.

17

18 INTERVENTIONS:

19 EVOLVING GUIDELINES AND PRACTICES:

20 In addition to the important consideration of ENI and ND, infection control practices  
21 recommended by international, national, regional and hospital-specific guidelines have had  
22 unintended consequences. For example, interventions intended to prevent maternal-neonatal  
23 transmission of virus have changed the routine practice of a planned normal birth. The decision



1 for an unplanned caesarean section delivery, separation of infants right after birth, strict isolation  
2 and visitation policies have resulted in a variety of medical and psychosocial effects on the  
3 mother-infant dyad and family.

4  
5 Different countries, international/national/regional organizations and hospitals have published  
6 recommendations on the management of a SARS-CoV-2-positive mother during labor, delivery,  
7 and for her infant (Figure 1). All recommendations were designed to balance alterations in  
8 delivery management to reduce SARS-CoV-2 transmission to the infant, with routine care  
9 recommendations that promote bonding and are beneficial to mother and infant. In the absence  
10 of data, guidelines were created ad hoc and with significant variation in practice<sup>23</sup>. Several of  
11 these recommendations for delivery of mothers with active SARS-CoV-2 were based on other  
12 infectious diseases (e.g. influenza), with little knowledge about the incidence and clinical  
13 presentation of neonatal SARS-CoV-2 infection.

14  
15 **OBJECTIVE:**

16 We intended to describe the frequency of ENI and ND, and their association with different DMI  
17 combinations as suggested by country or organization-specific guidelines, when compared with  
18 routine delivery practice.

19  
20 We categorized DMI into three broad categories: 1) physical environment, 2) delivery-specific,  
21 and 3) infant-care practices (Figure 1). Within each category there are individual interventions  
22 intended for infection prevention at various times during delivery. In different countries and birth  
23 centers, these interventions were applied in different combinations because of unique

1 circumstances dictating resource allocation, disease burden, and local practice. We have  
2 described these combinations with reference to several country-specific guidelines that were  
3 available at the inception of this review (see Appendix 1) <sup>24</sup>.

4

#### 5 **FACTORS NOT ADDRESSED**

6 Enteral feeding practices and post-partum behaviors also likely impact ENI and ND. As these are  
7 detailed and nuanced decisions often made independent of the DMI, enteral feeding are beyond  
8 the scope of this review.

9

10 It was also difficult to completely remove the risk of a SARS-CoV-2 positive healthcare worker  
11 or family member for ENI and ND. For many countries, the possibility of a healthcare worker  
12 contributing to early infection is a highly litigious aspect of infant care and will not be reported  
13 in case reports or databases. For pragmatic reasons, we will not be addressing potential  
14 transmission of SARS-CoV-2 from family members or healthcare workers to the neonate.

15

#### 16 **DESIGN**

17 The protocol for this review was submitted to PROSPERO ID CRD42021267892. Articles  
18 published 1 January 2020 - 31 December 2021 from Cochrane review databases, Medline and  
19 Google Scholar were searched. Primary screening was conducted by 2 reviewers (CSC and JYK)  
20 using specific search criteria (Appendix 2).

21 We included the following studies (listed in the order of the strength of evidence):

22 1. Randomized controlled trials

23 2. Quasi-randomized trials

1           3. Cohort studies

2           4. Case-control studies

3           5. Cross-sectional studies

4           6. Case series/case reports

5

6   Specific inclusion criteria included:

7           1. mothers with SARS-CoV-2 PCR positive status within 10 days before delivery or  
8           symptomatic at delivery with a positive test within 48h after delivery

9           2. delivery method described

10          3. infant SARS-CoV-2 PCR result known

11

12   **MAIN OUTCOME MEASURES:**

13   Types of DMI (see Appendix 3)

14          A. Physical environment (aerosolization and droplet management):

15               1. Negative pressure in delivery area

16               2. Separate room from delivery room

17               3. Distance of  $\geq 6$  feet from mother during resuscitation

18               4. Maternal masking during delivery compared to no maternal masking during  
19               delivery

20          B. Delivery-specific interventions (minimization of contact during delivery with maternal  
21          fluids):

22               1. Caesarean section for infection prevention

23               2. Early cord clamping compared to delayed cord clamping

1 C. Infant care practices (minimizing infant skin contact):

2 1. Infant cleaning/decontamination as soon as possible after resuscitation compared  
3 to routine skin care

4 2. Prevention of skin-to-skin contact after stabilization compared to skin-to-skin  
5 contact after stabilization

6

7 Primary outcomes

8 1. Confirmation of early neonatal SARS-CoV-2 infection by a positive PCR on any  
9 neonatal samples taken at 12 hours and up to 10 days of life.

10 2. Neonatal death occurring before 28 days of life.

11

12 Secondary outcomes were selected by their potential relationship with SARS-CoV-2 infection:

13 1. Maternal characteristics:

14 a. Age

15 b. maternal symptom severity (Appendix 4)

16 i. Asymptomatic

17 ii. Mild

18 iii. Moderate

19 iv. Severe

20 v. Critical

21 2. Delivery metrics:

22 a. Gestational age

23 b. Infant sex

- 1           c. Birth weight
- 2           d. Apgar scores at one minute and five minutes
- 3       3. Clinical status in SARS-CoV-2 positive infants (Appendix 4)
- 4           a. Asymptomatic
- 5           b. Mild
- 6           c. Moderate
- 7           d. Severe
- 8           e. Critical

9

## 10 **DATA COLLECTION AND ANALYSIS**

11   Cochrane search was used for the initial search (initial strategy). A combination of Medline and  
12   Google Search (updated strategy) was used by two review authors for later search and screening  
13   (JMH, LPB). Comparison of the initial and updated strategies found 96.5% overlap of the two  
14   strategies for publication identification and inclusion. Two review authors (CSC, JYK)  
15   independently screened all titles, abstracts and full-text reports for eligibility. They resolved any  
16   differences in decision between authors by discussion leading to consensus. They recorded the  
17   selection process in sufficient detail to complete a PRISMA flow diagram (Figure 2). They  
18   extracted data using a pilot-tested Microsoft Excel spreadsheet and a comprehensive list of  
19   included articles can be found in Appendix 5.

20

21   Primary outcomes were ENI and ND. Both outcomes were treated as binary variables. All  
22   analyses were carried out using individual patient level data. All maternal and infant  
23   characteristics were pooled using DerSimonian-Laird inverse variance method. Pooled results

1 were expressed as percentages with 95% confidence interval (95%CI) for categorical variables  
2 and as mean (95%CI) or median (95%CI), whichever appropriate, for continuous variables.  
3 Primary outcome analyses were carried out using logit transformation and random effect.  
4 Continuity correction was applied for all pooled results if any included study has 0 event. The  
5 heterogeneity of included studies was evaluated with  $I^2$  statistics, considering a value less than  
6 25% as low heterogeneity, 50-75% as medium heterogeneity and greater than 75% were  
7 considered as high heterogeneity. All the analyses were carried out using SAS version 9.4 (SAS  
8 Institute; Cary, NC, USA) and R ('meta' library).

9

## 10 **RESULTS**

11 Of 11,075 publications initially screened, 117 articles were selected for inclusion (Figure 2).  
12 Data used for this analysis from the 117 publications included 243 infants and 231 mothers.

13

14 Clinical characteristics are described in Table 1. The mean maternal age was 31.2 years. The  
15 majority, 31.3% [29.97, 32.49], of these women infected with SARS-CoV-2 showed moderate  
16 illness severity. 79% [69.2, 88.9] of women experienced cesarean-section delivery. The mean  
17 gestational age was 35.6 [34.2, 37.1] weeks. 58% [44.6, 72.2] of these cases were male infants.  
18 The mean birthweight was 2550 grams [2300, 2790]. Median Apgar scores were 8 [8, 8] at 1  
19 minute, and 9 [9, 10] at 5 minutes. ENI was described in 23.4% [18.2, 29.18] of cases. Early  
20 neonatal death <28 days was reported in 2.1% [0.67, 4.72] of cases.

21

22 Total cases of each delivery management intervention are depicted in Table 2:

1 67 cases reported on the physical environment designed to minimize aerosolization and droplets  
2 from the infected mother. Among 25 cases with information on the use of negative pressure in  
3 the delivery room, this DMI was used in 21 (85.5% [73.15, 97.79]). Among 34 cases with  
4 information on the use of a separate room for infant resuscitation or a distance of > 6 feet from  
5 the mother during the resuscitation, this DMI was used in 32 (94.3% [84.23, 100]). 38 cases  
6 contained information about maternal masking during delivery and all reported use of this DMI  
7 (100% [90.39, 100]).

8  
9 Among 59 cases with information on delivery-specific interventions designed to minimize  
10 contact during delivery with maternal secretions, use of cesarean section for infection prevention  
11 purposes was reported in 58: 41 reported use of this DMI (47.3% [28.72, 65.83]). 18 cases  
12 reported on early cord clamping and all reported use of this DMI (100% [86.03, 100]).

13  
14 Among 79 cases with information on infant care practices designed to minimize infant skin  
15 contact with infected secretions, 5 cases reported specifically on infant cleaning or  
16 decontamination right after the resuscitation: 4 reported use of this DMI (80% [40.8, 100]).  
17 Among 79 cases with information on preventing skin-to-skin with the mother after infant  
18 stabilization, all reported use of this DMI (100% [93.88, 100]).

19  
20 Primary outcomes are described in Table 3. Combination A describes physical environmental  
21 changes, combination B describes delivery-specific interventions and combination C describes  
22 infant care interventions. Combination 1) A only, 2) B only, 3) C only, 4) A plus B plus C, 5) A  
23 plus B without C, 6) B plus C without A, and 7) A plus C without B were evaluated for incidence

1 of the primary outcomes ENI and ND compared to routine care. Pooled frequencies of ENI and  
2 ND were reported as random effect with all DMI alone and DMI combinations (7 total  
3 comparisons). No routine care was described in these publications so the primary comparison of  
4 DMI combinations to routine care was not possible. Sample size for each combination was too  
5 small to conduct any valid comparison of the 6 different DMI combinations.

6  
7 Subgroup analyses of maternal illness severity and gestational age effects on ENI and ND are  
8 described in Appendix 6. Neither maternal illness severity nor gestational age had statistically  
9 significant effects on ENI or ND.

10

## 11 **DISCUSSION:**

12 This is the first systematic review of published cases describing specific interventions in delivery  
13 management that were recommended during the pandemic to reduce the possibility of ENI and  
14 ND before 28 days of life. While the pandemic has changed with the introduction of several  
15 vaccines and the exposure of most worldwide populations to SARS-CoV-2, the question of how  
16 best to protect infants from an airborne infection remains relevant.

17

18 Our review highlights significant publication biases inherent during the active phases of the  
19 pandemic including preferential publication of deliveries where management was altered without  
20 similar descriptions of outcomes for deliveries conducted in routine fashion, preferential  
21 publication of cases involving ENI and ND, and publication of multiple reports that did not  
22 include specific information regarding routine delivery management practices. These biases in  
23 publication along with limitations including lack of randomization, limited case numbers, and



1 limited data on postpartum care contribute to our ongoing inability to provide evidence for best  
2 practice delivery management modifications for reducing ENI and ND.

3  
4 Given our findings, it is uncertain what contribution delivery management interventions may  
5 play into neonatal outcomes. Instead, ENI and ND may be influenced by maternal illness  
6 severity prior to delivery, viral load during the pregnancy, and post-partum practices where mild  
7 to moderately symptomatic mothers could cohort with their infants.

8  
9 **CONCLUSIONS**

10  
11 Comparison of DMI to routine care was not possible in this systematic review. More data is  
12 needed to accurately assess the effect of these DMI on ENI and ND. We recommend investing in  
13 large, multinational, prospective database creation with specific attention to DMI to more  
14 systematically address the question of optimal delivery management for prevention of airborne  
15 transmission from mother to infant.

16  
17

1 ***Acknowledgements***

2 There was no funding for this publication.

3

4 **Contributions of authors**

5 CSC and JYK wrote the first version of the protocol and subsequent manuscript drafts. RS  
6 provided statistical support and contributed to methods. VM and KM contributed to data  
7 extraction. EHA provided obstetric expertise. JMH and LPB reviewed and extracted articles  
8 using the updated search strategy. All other authors have contributed to and approved the current  
9 version.

10

11 **Declarations of interest**

12 JYK has no interests to declare

13 CSC has no interests to declare

14 RS has no interests to declare

15 VM has no interests to declare

16 KLB has no interests to declare

17 KM has no interests to declare

18 EHA has no interests to declare

19 KTY has no interests to declare

20 JMH has received compensation as neonatology board member of AbbVie France; fees from  
21 Nestec SA (Switzerland) and Nutricia Research (Holland) for consulting service on clinical  
22 trials; and from Baxter (USA) as a speaker in an international education program on advanced  
23 nutrition; all were outside and unrelated to the submitted work.

1 LPB has received funding from the NIH, from the Gerber Foundation and from the Children's  
2 Medical Center Foundation in Dallas TX for unrelated research.

3

4 Sources of support: Internal sources

5 UT Southwestern Medical Center, Dallas, TX, USA

6 Division of Neonatal-Perinatal Medicine

7

8 External sources: Vermont Oxford Network, USA

9 Cochrane Neonatal Reviews are produced with support from Vermont Oxford Network, a  
10 worldwide collaboration of health professionals dedicated to providing evidence-based care of  
11 the highest quality for newborn infants and their families.

12

13

14


1   References

- 2   1.     Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected  
3         with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506.
- 4   2.     WHO. Pneumonia of unknown cause – China. *World Health Organization*. Disease  
5         Outbreak News Online2020.
- 6   3.     Qadri F, Mariona F. Pregnancy affected by SARS-CoV-2 infection: a flash report from  
7         Michigan. *J Matern Fetal Neonatal Med*. 2020:1-3.
- 8   4.     Smith ER, Oakley E, Grandner GW, Ferguson K, Farooq F, Afshar Y, et al. Adverse  
9         maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2  
10        infection: an individual participant data meta-analysis. *BMJ Glob Health*. 2023;8(1).
- 11 5.     Zaigham M, Andersson O. Maternal and perinatal outcomes with COVID-19: A  
12        systematic review of 108 pregnancies. *Acta Obstet Gynecol Scand*. 2020.
- 13 6.     Chandrasekharan P, Vento M, Trevisanuto D, Partridge E, Underwood MA, Wiedeman J,  
14        et al. Neonatal Resuscitation and Postresuscitation Care of Infants Born to Mothers with  
15        Suspected or Confirmed SARS-CoV-2 Infection. *Am J Perinatol*. 2020.
- 16 7.     Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in  
17        Different Types of Clinical Specimens. *JAMA*. 2020.
- 18 8.     Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al.  
19        SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a  
20        Clinically Proven Protease Inhibitor. *Cell*. 2020;181(2):271-280.e278.
- 21 9.     Li M, Chen L, Zhang J, Xiong C, Li X. The SARS-CoV-2 receptor ACE2 expression of  
22        maternal-fetal interface and fetal organs by single-cell transcriptome study. *PLoS One*.  
23        2020;15(4):e0230295.


- 1 10. Pringle KG, Tadros MA, Callister RJ, Lumbers ER. The expression and localization of  
2 the human placental prorenin/renin-angiotensin system throughout pregnancy: roles in  
3 trophoblast invasion and angiogenesis? *Placenta*. 2011;32(12):956-962.
- 4 11. Valdés G, Neves LA, Anton L, Corthorn J, Chacón C, Germain AM, et al. Distribution of  
5 angiotensin-(1-7) and ACE2 in human placentas of normal and pathological pregnancies.  
6 *Placenta*. 2006;27(2-3):200-207.
- 7 12. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2  
8 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic  
9 target. *Intensive Care Med*. 2020;46(4):586-590.
- 10 13. Xiao AT, Tong YX, Zhang S. Profile of RT-PCR for SARS-CoV-2: a preliminary study  
11 from 56 COVID-19 patients. *Clin Infect Dis*. 2020.
- 12 14. Zamaniyan M, Ebadi A, Aghajanpoor Mir S, Rahmani Z, Haghshenas M, Azizi S.  
13 Preterm delivery in pregnant woman with critical COVID-19 pneumonia and vertical  
14 transmission. *Prenat Diagn*. 2020.
- 15 15. Baud D, Greub G, Favre G, Gengler C, Jaton K, Dubruc E, et al. Second-Trimester  
16 Miscarriage in a Pregnant Woman With SARS-CoV-2 Infection. *JAMA*. 2020.
- 17 16. Alzamora MC, Paredes T, Caceres D, Webb CM, Valdez LM, La Rosa M. Severe  
18 COVID-19 during Pregnancy and Possible Vertical Transmission. *Am J Perinatol*. 2020.
- 19 17. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and  
20 intrauterine vertical transmission potential of COVID-19 infection in nine pregnant  
21 women: a retrospective review of medical records. *Lancet*. 2020;395(10226):809-815.
- 22 18. Dong L, Tian J, He S, Zhu C, Wang J, Liu C, et al. Possible Vertical Transmission of  
23 SARS-CoV-2 From an Infected Mother to Her Newborn. *JAMA*. 2020.

- 1 19. Zeng H, Xu C, Fan J, Tang Y, Deng Q, Zhang W, et al. Antibodies in Infants Born to  
2 Mothers With COVID-19 Pneumonia. *JAMA*. 2020.
- 3 20. Palatnik A, McIntosh JJ. Protecting Labor and Delivery Personnel from COVID-19  
4 during the Second Stage of Labor. *Am J Perinatol*. 2020.
- 5 21. Mick P, Murphy R. Aerosol-generating otolaryngology procedures and the need for  
6 enhanced PPE during the COVID-19 pandemic: a literature review. *J Otolaryngol Head*  
7 *Neck Surg*. 2020;49(1):29.
- 8 22. Zeng L, Xia S, Yuan W, Yan K, Xiao F, Shao J, et al. Neonatal Early-Onset Infection  
9 With SARS-CoV-2 in 33 Neonates Born to Mothers With COVID-19 in Wuhan, China.  
10 *JAMA Pediatr*. 2020.
- 11 23. Lavizzari A, Klingenberg C, Profit J, Zupancic JAF, Davis AS, Mosca F, et al.  
12 International comparison of guidelines for managing neonates at the early phase of the  
13 SARS-CoV-2 pandemic. *Pediatr Res*. 2020.
- 14 24. D D, F K, E F, C B, V H, AT P, et al. Review of clinical practice guidelines for the care  
15 of pregnant women (and their babies) during COVID-19 (Protocol). Cochrane Pregnancy  
16 and Childbirth COVID Group: Cochrane Pregnancy and Childbirth; 2020.
- 17

**Figure 1. Depiction of delivery management interventions (DMI).** At minimum a single intervention from category A – Physical Environment, category B – Delivery-Specific, or category C – Infant Care in combination or alone are evaluated for the primary outcomes and are compared to routine care. The different categories of interventions are 1) Combo A alone, 2) Combo B alone, 3) Combo C alone, 4) Combo A + B + C, 5) Combo A + B not C, 6) Combo B + C not A, and 7) Combo A + C not B.



**Figure 2. PRISMA Flow Diagram of included studies.** Search strategies included Cochrane search 1 January 2020 to 22 July 2020, PubMed and Google Scholar Search 22 July 2020 to 31 December 2020, and PubMed and Google Scholar Search 1 January 2021 to 31 December 2021.



From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71. For more information, visit: <http://www.prisma-statement.org/>



**Table 1. Clinical characteristics of maternal-infant pairs affected by perinatal COVID-19**

<b>Characteristics</b>	<b>Summary</b>
Maternal Age at delivery (years) <sup>□</sup> (n = 222)	31.23 [29.97, 32.49]
Maternal illness severity <sup>□</sup> (n = 228)	
Asymptomatic	10.01 [0.00, 20.65]
Mild	28.83 [14.40, 43.26]
Moderate	31.26 [17.00, 45.52]
Severe	10.56 [ 3.50, 17.62]
Critical	8.30 [1.58, 15.03]
Actual delivery mode <sup>□</sup> (n = 231)	
Cesarean section	79.04 [69.19, 88.89]
Vaginal delivery	20.96 [11.11, 30.81]
Gestational age at birth (weeks) <sup>□</sup> (n = 235)	35.64 [34.20, 37.08]
Male sex <sup>□</sup> (n = 128)	58.41 [44.62, 72.20]
Birthweight (kg) <sup>□</sup> (n = 183)	2.55 [2.30, 2.79]
Apgar score at 1 min <sup>□</sup> (n = 225)	8 [8, 8]
Apgar score at 5 min <sup>□</sup> (n = 225)	9 [9, 10]
Early Neonatal Infection <sup>□</sup>	23.36 [18.20, 29.18]
Early Neonatal Death <28 days <sup>□</sup>	2.05 [0.67, 4.72]

Notes: <sup>□</sup> Summary is expressed as median [95%CI]. <sup>□</sup> Summary is expressed as mean [95%CI]. <sup>□</sup> Summary is expressed as percentage [95%CI]. CI represents confidence interval.

**Table 2. Totals of infants and mothers with described delivery management interventions.**

<b>Delivery Management Intervention</b>	<b>Number of infants or mothers</b>	<b>Percentages (95% CI)</b>
<b>A: Physical environment (aerosolization and droplet management)</b>	<b>67</b>	
Negative pressure in delivery room	21/25	85.47 [73.15, 97.79]
Separate room for resuscitation of infant or Distance of $\geq 6$ feet from mother during resuscitation	32/34	94.33 [84.23, 100.00]
Maternal masking during delivery	38/38	100.00 [90.39, 100.00]
<b>B: Delivery-specific interventions (minimization of contact during delivery with maternal fluids)</b>	<b>59</b>	
Caesarean section for infection prevention purpose	41/58	47.27 [28.72, 65.83]
Early cord clamping	18/18	100.00 [86.03, 100.00]
<b>C: Infant care practices (minimization of infant skin contact)</b>	<b>79</b>	
Infant cleaning or decontamination right after resuscitation	4/5	80.00 [40.80, 100.00]
Prevent skin-to-skin after stabilization	79/79	100.00 [93.88, 100.00]
<p>Notes:</p> <ul style="list-style-type: none"> <li>• Denominator represents # of participants with reported (yes/no) particular exposures while numerator represents number of mothers /children had that particular exposure. Participants were not included in the analysis, if there was any missing exposure.</li> <li>• DerSimonian-Laird inverse variance estimator were used to pool the results. Simple approximation with continuity correction of 0.5 in studies with zero cell frequencies was applied. Variables were expressed as percentages (95%CI). CI represents confidence interval.</li> </ul>		

**Table 3. Primary outcomes of early neonatal infection and neonatal death by delivery management interventions *individually by category and in combinations of different categories.***

Combinations	Early neonatal SARS-CoV-2 infection			Neonatal death occurring before 28 days of life		
	n/N	Percentage (95% confidence interval)	I <sup>2</sup> (%)	n/N	Percentage (95% confidence interval)	I <sup>2</sup> (%)
Combo A only	7/23	37.29 [21.36; 56.57]	0	1/22	23.98 [12.56; 40.92]	0
Combo B only	1/24	13.38 [ 3.97; 36.60]	5	0/24	9.62 [2.77; 28.45]	0
Combo C only	8/22	43.45 [25.50; 63.30]	0	0/22	20.86 [10.51; 37.17]	0
Combo A + B + C	9/18	49.64 [29.77; 69.62]	0	0/18	22.34 [11.01; 40.07]	0
Combo A + B NOT C	1/2	50.00 [ 9.42; 90.58]	0	0/2	25.00 [3.35; 76.22]	0
Combo B + C NOT A	2/15	30.83 [ 8.10; 69.27]	26	0/15	15.92 [4.55; 42.93]	0
Combo A + C NOT B	11/24	47.18 [31.46; 63.48]	0	1/24	25.91 [15.06; 40.81]	0
Routine Care	0/0	-		0/0	-	-

Note: Combination A describes physical environmental changes. Combination B describes delivery specific interventions. Combination C describes infant care interventions. Logit transformation and random effects were used. Continuity correction was applied to all if any one study had 0 event. I<sup>2</sup> represent heterogeneity between studies.